Ireland Immunotherapy Market to be Dominated by Supermarkets and Hypermarkets through 2028
The advancements in biotechnology and genomics are
expected to drive the growth of Ireland immunotherapy market in the forecast
period, 2024-2028.
According to
TechSci Research report, “Ireland
Immunotherapy Market
- By Region, Competition Forecast and Opportunities, 2018-2028”, Ireland immunotherapy market is anticipated to grow at an impressive rate
in the forecast period, 2024-2028. This can be ascribed to the rising
demand for cancer treatment with medical benefits such as managing health
issues like as tumor reduction, improved survival rate, disease control and
progression prevention, palliative care, and symptoms relief along with growing
preference for personalized treatment among people are facing cancer related
issues across the region. Additionally, rapid advances in science and
technology, increasing healthcare expenditure, changes in living habits,
burgeoning aging population, and rising interest in attaining wellness will
escalate the growth of Ireland immunotherapy market in coming years. Besides, emergence
of new development novel immune checkpoint, CAR-T cell therapies, and
combination therapies will further be expected to support the Ireland
immunotherapy market growth.
However, the resistance of immunotherapy in Ireland
can be lack of response, and not all patients respond favorably to immunotherapy,
and some may develop resistance over time which can slowing down the growth of Ireland
immunotherapy market in the forecast period. Similarly, there is a lot of ethical
considerations, such as equitable access to immunotherapy, balancing potential
benefits with risks, and ensuring patient autonomy in decision-making which may
hamper the Ireland immunotherapy market growth during the forecast period.
Also, immunotherapy may be given as maintenance therapy, where treatment is
continued for an extended period to help prevent disease recurrence or
progression. Maintenance immunotherapy can be given for a year or more,
depending on the individual patient's condition and treatment response which
can further restrict the growth of Ireland immunotherapy market.
Browse over XX Market
Data Figures spread through XX Pages and an in-depth TOC on "IrelandImmunotherapy Market.”
The Ireland immunotherapy market can be segmented by product type, form, distribution channel,
application, end user, and by region.
Based on technology
type, the Ireland immunotherapy market can be segmented into monoclonal antibodies, cytokines &
immunomodulators, inhibitors, and others. The monoclonal antibodies segment
dominated the market in 2022 and is expected to continue maintaining its
dominance throughout the forecast period. This can be ascribed to the fact that
they are designed to target specific proteins or receptors on cancer cells or
immune cells, helping to enhance the immune response against cancer. Monoclonal
antibodies have been extensively studied and approved for the treatment of
various cancers, including melanoma, lung cancer, breast cancer, and more across
the region.
Based on indication,
the market can be segmented into oncology,
autoimmune diseases, infectious diseases, and others. The infectious
diseases segment is expected to dominate during the forecast period because they
are predominantly associated with cancer as well as autoimmune diseases. Also, there
are ongoing efforts to explore its potential in infectious diseases.
Immunotherapeutic approaches, such as monoclonal antibodies and immune-boosting
agents, are being investigated for the treatment and prevention of certain
infectious diseases, including viral infections like COVID-19.
Major companies
operating in Ireland immunotherapy market are:
- B Bristol Myers Squibb Co.
- Merck Sharp & Dohme (MSD)
Corp
- Pfizer Inc
- Roche AG
- Eli Lilly & Co
- AstraZeneca PLC
- Novartis AG
- Janssen Sciences Ireland UC
In 2019-2020.
Lilly has made 18 acquisitions and 58 investments Loxo Oncology acquire for
USD8 billion and IN 2020 acquire Dermiria for USD 1.10 billion.
These have been
significant developments in the company's portfolio expansion strategy.
AstraZeneca has invested almost USD40 billion on cardiovascular disease
acquisitions over the past four years through six deals. AstraZeneca has also
participated in five deals related to oncology and five deals related to
respiratory diseases during this time.
In 2022,
Novartis announced it had reached an agreement with Sterling Pharma Solutions,
a leading global development and manufacturing company, to produce medicine for
Novartis (active pharmaceutical ingredient (API)) in Ireland. Sterling Pharma
Solutions produces Novartis APIs for cardiology, immunology, and oncology
medicines. The production facilities secured a USD 16 million investment from
Novartis, to manufacture a significant cardiovascular medicine on the site.
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“Ireland
Immunotherapy is expected to dominate the market during the forecast period on
account of the rising demand for cancer treatment with medical benefits along
with growing preference for personalized treatment across the region.
Furthermore, trend of personalized treatment is growing, particularly among
individuals with cancer-related medical conditions, where generic treatment is available
for some types of cancer which will further contributing to demand for Ireland
immunotherapy market during the forecast period. Besides, increasing concern
about healthy lifestyles and increasing expenditure on health and wellness is
further expected to create lucrative opportunities for the market growth” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Ireland Immunotherapy Market, By Technology (Monoclonal Antibodies, Cytokines
& Immunomodulators, Inhibitors, and Others), By Indication (Oncology,
Autoimmune Diseases, Infectious Diseases, and Others), By End User (Hospitals
& Clinics, Ambulatory Care Centers, Research & Academic Institutions, and
Others), By Region, Competition, Forecast and
Opportunities, 2028”, has evaluated
the future growth potential of Ireland immunotherapy market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Ireland immunotherapy market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: www.techsciresearch.com